| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
|
Medicine details |
|
| Medicine name | panobinostat (Farydak®) |
| Formulation | 10 mg, 15 mg, 20 mg capsule |
| Reference number | 790 |
| Indication | In combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 03/07/2015 |
| NICE guidance | TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |